Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — Proactive Investors CEO Series Sydney & Melbourne 2018
18 slides from Kazia Therapeutics's conference presentation, Mar 19, 2018
Slide 1: An emerging oncology developer with two clinical-stage programs
An emerging oncology developer with two clinical-stage programs Proactive Investors CEO Series Sydney & Melbourne 20 & 21 March 2018
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual
Slide 3: Investment Highlights
Investment Highlights 1 Cancer-focused biotech with two distinct therapies in clinical trials - GDC-0084 entering phase II trial for brain cancer - Cantrixil currently in phase I trial for ovarian cancer 2 Business strategy focused on owning assets at a critical stage in their value life-cycle, deli
Slide 4: Kazia is focused on development of high-potential novel therapies for poorly-served cancers
Kazia is focused on development of high-potential novel therapies for poorly-served cancers Partner with big pharma for late-stage development to bring to market Bring in under-valued assets from other pharmaceutical companies Conduct focused clinical trials Identify optimal patient groups Understan
Slide 5: A strong team brings international experience in big pharma and early-stage biotech
A strong team brings international experience in big pharma and early-stage biotech Board Scientific Advisory Board Iain Ross Chairman Executive and Board roles in pharma and small biotech Bryce Carmine Deputy Chairman 36 years executive experience in Eli Lilly Steven Coffey Non-Executive Director C
Slide 6: Kazia is listed on ASX and NASDAQ, with a market cap of ~AU$ 27 million
Kazia is listed on ASX and NASDAQ, with a market cap of ~AU$ 27 million Market Capitalisation AU$ 27 million Shares on Issue 48.3 million (35% US, 65% Australia) Current Assets* ~AU$ 14.8 million Listing ASX: KZA NASDAQ: KZIA (1:10 ratio) Share Price (AU$) Outstanding Options / Warrants ~6 million A
Slide 7: Our efforts are attracting increasing attention from media and the investment community
Our efforts are attracting increasing attention from media and the investment community
Slide 8: Two clinical programs, with value-driving inflection points providing newsflow during 2018
Two clinical programs, with value-driving inflection points providing impactful newsflow during 2018 *MTD = Maximum Tolerated Dose GDC-0084 Glioblastoma Multiforme (GBM) Cantrixil Ovarian Cancer Brain-penetrant PI3K inhibitor, developed to completion of phase I by Genentech Third-generation benzopyr
Slide 9: GDC-0084 Phase II Glioblastoma Multiforme
GDC-0084 Phase II Glioblastoma Multiforme
Slide 10: Glioblastoma is the most common and most aggressive form of primary brain cancer
Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer Lung 14 million cancer cases per annum Breast Colon Prostate Stomach No clear cause or strong risk factors 3-4 months untreated survival 12-15 months average survival with treatment Any age, but most common in 60s
Slide 11: Current standard of care is essentially ineffective in up to 65% of GBM cases
Current standard of care is essentially ineffective in up to 65% of GBM cases Source: ME Hegi, A-C Diserens, T Gorlia, et al. (2005). N Engl J Med 352:997-1003 Standard of Care (‘Stupp Regimen’) Debulking surgery where possible Radiotherapy + temozolomide Temozolomide maintenance therapy 6 weeks 4w
Slide 12: Growing public attention for brain cancer highlights need for new treatment options
Growing public attention for brain cancer highlights need for new treatment options There is increasing recognition of the need to find treatment options for patients diagnosed with GBM Senator John McCain’s diagnosis in July 2017 highlighted glioblastoma and focused attention on the need for new tr
Slide 13: The PI3K pathway is central to many types of cancer, and especially to GBM
The PI3K pathway is central to many types of cancer, and especially to GBM PI3K A central biochemical control mechanism in the growth of cells PI3K ACTIVATED PI3K INHIBITED TUMOUR GROWTH TUMOUR INHIBITION 85 – 90% of glioblastoma cases have PI3K ‘switched on’ GDC-0084 switches off PI3K activation, a
Slide 14: The PI3K class has been validated by approval of a new therapy in September 2017
The PI3K class has been validated by approval of a new therapy in September 2017 Two PI3K inhibitors now successfully brought to market Zydelig (idelalisib) [Gilead] Aliqopa (copanlisib) [Bayer] Neither drug is brain-penetrant, so are unlikely to rival GDC-0084 Demonstrates that PI3K is a validated
Slide 15: Genentech's phase I clinical study of GDC-0084 established dosing and showed favourable safety
Genentech’s phase I clinical study of GDC-0084 established dosing and showed favourable safety Efficacy Signals Safety Phase I safety trial conducted by Genentech 47 patients enrolled with advanced glioma (grade 3/4); average of three prior lines of therapy Most common adverse events were oral mucos
Slide 16: Kazia is about to initiate a phase II clinical trial of GDC-0084 in glioblastoma
Kazia is about to initiate a phase II clinical trial of GDC-0084 in glioblastoma Transfer of IND with US FDA from Genentech and updating ü Design of phase II clinical study with input from clinicians ü Manufacture of drug substance into capsules for clinical trial use ü Engagement of contract resear
Slide 17: Other companies focused on the PI3K pathway have been highly-valued in the market
Single asset company with one PI3K inhibitor in phase I human trials US$ 130 million Market Cap One PI3K inhibitor in phase II human trials, one other drug in phase III, and two in animal testing US$ 1.2 billion Market Cap One PI3K inhibitor in phase II human trials Acquired by big pharma in 2011 fo
Slide 18: Kazia Therapeutics
KAZIA THERAPEUTICS www.kaziatherapeutics.com Twitter: @KaziaTx
Kazia Therapeutics — Proactive Investors CEO Series Sydney & Melbourne 2018 on 6ix